At the news
? NEUTRALIMPACT 5/10 8-K filed Nov 9, 2026 at 16:30 ET
Rafael Holdings filed an 8-K furnishing an investor presentation that reviews Phase 3 topline data for remibetadex in Niemann-Pick disease type C (NPC). The primary endpoint was not statistically significant (p=0.19), but a prespecified analysis in patients on miglustat/leucine showed a 71% relative slowing of disease progression (p=0.046). An NDA was submitted to the FDA in October 2026 with a potential PDUFA target around mid-2027 if priority review is granted.
- Phase 3 TransportNPC primary endpoint (4DNPCSS change at Week 96) not statistically significant: difference 0.81, p=0.19
- Prespecified analysis in patients on miglustat/leucine (n=78) showed 71% relative slowing of disease progression, difference 1.11, p=0.046
- NDA submitted to FDA in October 2026; Day 60 filing decision expected Dec. 27, 2026
- Potential PDUFA target date ~June 2027 if priority review granted
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access